Bayer say VEGF Trap-Eye shows promise as mCNV treatment

FRANKFURT, June 6 Thu Jun 6, 2013 2:43am EDT

FRANKFURT, June 6 (Reuters) - Bayer said on Thursday its drug VEGF Trap-Eye had demonstrated to improve visual acuity in a late-stage trial on patients suffering from myopic choroidal neovascularization (mCNV).

Bayer co-develops the eye drug, also known as Eylea, with Regeneron.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.